Twist Bioscience Corporation · NASDAQ:TWST
Twist Bioscience — 37th Annual JPM Healthcare Conference 2019
33 slides from Twist Bioscience's conference presentation, Jan 7, 2019
Slide 1: Powering the Synthetic Biology and Genomics Revolutions
Exhibit 99.1 Powering the Synthetic Biology and Genomics Revolutions / 37th Annual JPM HC conference / January 2019 / TwistBioscience / #WeMakeDNAExhibit 99.1 Powering the Synthetic Biology and Genomics Revolutions / 37th Annual JPM HC conference / January 2019 / TwistBioscience / #WeMakeDNA
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. In particular, statements regarding future economic performance, finances, and expectations and objectives of management constitute forward-looking statements. Forward-looking statements can be identified by the fact that t
Slide 3: Writing Synthetic DNA on Silicon Platform
Writing Synthetic DNA on Silicon Platform Fueling the Industrialization of Synthetic Biology KEY ADVANTAGES OF WRITING DNA ON SILICON MINIATURIZATION THROUGHPUT LOW COST VERSATILE PLATFORM 3-6 10 less volume of required reagents 20M oligos/month Driving adoption and new applications Broad applicatio
Slide 4: Our Versatile DNA Synthesis Platform Has Broad Applications
Our Versatile DNA Synthesis Platform Has Broad Applications GENE DNA/ANTIBODY NGS DRUG DISCOVERY DNA DNA CRISPR & DEVELOPMENT SYNTHESIS LIBRARIES BIODETECTION DATA STORAGE COMPUTING Product Available Developing Product Available Product Available Launched Developing Potential Twist’s versatile DNA s
Slide 5: Our Strategy
Our Strategy GENOMICS: TARGETED NGS SYNTHETIC BIOLOGY: GENE SYNTHESIS OPEN NEW MARKETS Near-term strategic priorities Long-term initiatives • Augment our product offering to meet the • Lead the Buyer market Twist’s advantages in… growing needs of our existing and • Convert Makers into Buyers potenti
Slide 6: Twist Bioscience Pipeline
Twist Bioscience Pipeline MARKET OPPORTUNITIES EXPLORATION PROOF OF CONCEPT BETA COMMERCIAL NEXT STEPS • Continue to drive growth, Synthetic Biology: add market share Synthetic Genes, • 5kb genes, Twist API DNA Libraries and 1 Oligo Pools • NPI roadmap • Continue converting NGS pilot accounts to pro
Slide 7: Twist's Platform Technology Addresses Multiple Large Market Opportunities
TWIST’S PLATFROM TECHNOLOGY ADDRESSES Multiple Large Market Opportunities LARGE MARKET OPPORTUNITIES LARGE MARKET $1.3B $0.5B $35B+ DRUG DISCOVERY/ SYNTHETIC GENOMICS: DATA STORAGE DEVELOPMENT BIOLOGY TARGETED NGS • Competitive • Fast Customization • High Quality Diversity • Permanence Turnaround Ti
Slide 8: Synthetic Biology is a Rapidly Growing $4B Opportunity
Synthetic Biology is a Rapidly Growing $4B Opportunity NEEDS NEW APPLICATIONS FOR SYNTHETIC DNA Healthcare • Antibodies / TCR • Better drug development tools to lessen time • Vaccines and lower costs • Immuno and Cancer Therapies • More effective diagnostic tools for DNA • Small Molecule Drug Manufa
Slide 9: Gene Synthesis Market: Buyers and Makers
Gene Synthesis Market: Buyers and Makers $1.3B / Year Small Scale, “Make” Large Scale, Academic Users Synthesis Supplies Price-Sensitive Commercial Users (Enzymes, Primers, Cells, Plates) Value: Speed, Throughput “Buy” and Quality “ ” I Hate Synthetic DNA Cloning $950M “ ” $300M Can’t get what I nee
Slide 10: Rewriting DNA with the Power of Silicon
Rewriting DNA with the Power of Silicon 121 devices per cluster 96 WELL PLATE TWIST SILICON PLATFORM makes 1 gene can make 9,600 gene Developing Game-Changing Throughput and Cost through Quality and Speed at Scale Twist Bioscience CorporationRewriting DNA with the Power of Silicon 121 devices per cl
Slide 11: Twist Value Proposition: Key Advantages
TWIST VALUE PROPOSITION Key Advantages HIGH QUALITY UNIQUE CUSTOMER EXPERIENCE LOWER COST UNPRECEDENTED THROUGHPUT / SCALE CONSISTENT RELABILITY COMPETITIVE TURNAROUND TIME COMPREHENSIVE PRODUCT OFFERING Twist Bioscience Corporation 11TWIST VALUE PROPOSITION Key Advantages HIGH QUALITY UNIQUE CUSTOM
Slide 12: A Unique Way to Order your DNA Online
A Unique Way to Order your DNA Online … Twist Bioscience Corporation 12A Unique Way to Order your DNA Online … Twist Bioscience Corporation 12
Slide 13: E-Commerce is Enabling Capture of Long Tail
E-Commerce is Enabling Capture of Long Tail E-COMMERCE IMPACT Sequence Intake Q1-18 VS. Q1-19* Invoicing Codon Optimization 45% lower PO size as we reach long tail Shipping Shipping & Taxes 3.5x more orders Notifications Quoting Tracking Payment Order *unaudited, ex-Ginkgo, synbio Twist Bioscience C
Slide 14: Now Available: 5kb Genes API at disruptive price
Now Available: 5kb Genes API at disruptive price • Seamless integration • Increase serviceable market • Increase service stickiness • Enable maker to buyer conversion WITHOUT API 3.2kb 5kb WITH API Twist Bioscience Corporation 14Now Available: 5kb Genes API at disruptive price • Seamless integration
Slide 15: Disease Diagnostics
Disease Diagnostics Targeted NGS is enabling reading of patient’s and/or pathogen’s DNA to inform precision or personalized medical treatment • Reduced sequencing cost per sample • Faster time to results • Increased sensitivity / complete coverage of difficult regions Twist Bioscience Corporation 15
Slide 16: Targeted NGS value chain
Targeted NGS value chain Library Prep • Enzyme, Buffer, Primers, Barcodes $0.5B • Oligos (10s to 100,000s, pooled, high quantities) SAM • Catalog: All Exome (~20,000 known human genes) Capture • Custom: panels of 1 to 1,000s of genes, customer specific • Buffer, beads, enzyme • DNA sequencing Sequen
Slide 17: Targeted NGS – Strong Value Proposition
Targeted NGS – Strong Value Proposition PERFORMANCE / COST • High Uniformity • Low Sequencing Costs CUSTOMIZATION • 2-3 Weeks Design to Production • On Custom and Exome Panels FULL KIT • All Consumables From One Provider Twist Bioscience Corporation 17Targeted NGS – Strong Value Proposition PERFORMA
Slide 18: NGS Conversion – Pilot to Production Pipeline
NGS Conversion – Pilot to Production Pipeline Test in customer workflow; Optimization Pricing and commercial for specifications discussions Production Pilot testing: initial use tests • Pilot to production cycle typically requires 9 to 18 months • First Twist customers moved to production Q4 2018 •
Slide 19: Strong Orders Growth
Strong Orders Growth QUARTERLY ORDER VALUE ($M) FY’18: $39.4M Y/Y growth 107% Non-ginkgo $12.8 Ginkgo $10.7 $8.5 $7.4 $10.6 $6.2 $8.2 $6.7 $4.5 $4.9 $4.2 $3.7 $2.8 $2.7 $2.7 $1.2 $2.5 $2.5 $2.5 $2.2 $1.8 $1.8 $1.6 $1.5 Oct-Dec 16 Jan-Mar 17 Apr-Jun 17 Jul-Sep 17 Oct-Dec 17 Jan-Mar18 Apr-Jun18 Jul-Se
Slide 20: Customer Growth
Customer Growth CUSTOMER COUNT 151% 719 YoY growth % 195% 286 97 FY 2016 FY 2017 FY 2018 Twist Bioscience Corporation 20Customer Growth CUSTOMER COUNT 151% 719 YoY growth % 195% 286 97 FY 2016 FY 2017 FY 2018 Twist Bioscience Corporation 20
Slide 21: Revenue Growth FY16-19
Revenue Growth FY16-19 FULL-YEAR REVENUE ($M) Revenue CAGR (2016-19) $46-$48* +171% $25.4 $10.7 $2.3 FY 2016 FY 2017 FY 2018 FY 2019 Total *Twist FY19 Revenue Guidance: $46M-$48M Twist Bioscience Corporation 21Revenue Growth FY16-19 FULL-YEAR REVENUE ($M) Revenue CAGR (2016-19) $46-$48* +171% $25.4
Slide 22: Twist's Platform Extends to Other Growth Verticals
TWIST’S PLATFROM EXTENDS TO Other Growth Verticals LARGE MARKET $1.3B $0.5B $35B+ DRUG DISCOVERY/ SYNTHETIC GENOMICS: DATA STORAGE DEVELOPMENT BIOLOGY TARGETED NGS • Competitive • Fast Customization • High Quality Diversity • Permanence Turnaround Time Hits / Leads • Performance • Density • Lower Co
Slide 23: Novel Protein Libraries for Drug Discovery
Novel Protein Libraries for Drug Discovery To Enable Efficiency in Drug Discovery Precise Introduction of Variants, From Needle To Stack Diversity that Enables Screening in a Haystack of Needles Efficiency Gene Synthesis • Random diversity • Explicit Single Site • Biased representation • Even repres
Slide 24: Expanding Drug Discovery Capabilities
Expanding Drug Discovery Capabilities Enables Tackling Bio-Betters and Hard-to-Drug Targets Bio-Betters CUSTOM SOFTWARE High Diversity, High Quality Molecules ANTIBODY OPTIMIZATION • Affinity (pM) • Immunogenicity TAO Software • Solubility • Half-life • Druggability • Expression “Human Repertoire In
Slide 25: Twist Biopharma Proof-of-Concept: GPCR Library and Bio-Better
Twist Biopharma Proof-of-Concept: GPCR Library and Bio-Better GPCR: Target 1 Bio-Better: PDL1 inhibitor “Human Repertoire Inspired” CUSTOM SOFTWARE Parental Antibody (>500 nM) Optimized Antibody (570 pM) A Panel of Cell Target(+) IgGs Identified Kd =1.1 nM 1000x fold Affinity Increase Of These Cell
Slide 26: Twist's Platform Extends to Other Growth Verticals
TWIST’S PLATFROM EXTENDS TO Other Growth Verticals LARGE MARKET $1.3B $0.5B $35B+ DRUG DISCOVERY/ SYNTHETIC GENOMICS: DATA STORAGE DEVELOPMENT BIOLOGY TARGETED NGS • Competitive • Fast Customization • High Quality Diversity • Permanence Turnaround Time Hits / Leads • Performance • Density • Lower Co
Slide 27: DNA: Nature's Choice for Data Storage
DNA: Nature’s Choice for Data Storage MAN- MADE, STABLE FOR 1000s of YEARS NOT PERMANENT 20,000 Years ago 40,000 Years ago 560,000 - 780,000 Years ago Twist Bioscience Corporation 27DNA: Nature’s Choice for Data Storage MAN- MADE, STABLE FOR 1000s of YEARS NOT PERMANENT 20,000 Years ago 40,000 Years
Slide 28: Data Storage in DNA
Data Storage in DNA 1 Coding 2 Synthesis 3 Storage 4 Retrieval 6 Decoding 5 Sequencing Permanence l Density l Random Access l Universal format Twist Bioscience Corporation 28Data Storage in DNA 1 Coding 2 Synthesis 3 Storage 4 Retrieval 6 Decoding 5 Sequencing Permanence l Density l Random Access l
Slide 29: DNA Data Storage Trends and Projections
DNA Data Storage Trends and Projections We believe new DNA technologies and cost efficiencies could surpass mature IT hardware solutions in 3–5 years $100 $1 Raw Oligo Pool cost** *** (3) Sequencing Price** (1) $0.01 $0.0001 $0.000001 Hard Drive Price (converted*)** (2) $0.00000001 Technologies opti
Slide 30: Experienced Management Team
Experienced Management Team Emily LeProust, PhD Bill Banyai, PhD Bill Peck, PhD Jim Thorburn Aaron Sato President, CEO, Co-founder COO, Co-founder CTO, Co-founder CFO CSO, Twist Pharma Mark Daniels Ray Tabibiazar Patrick Finn, PhD Patrick Weiss Paula Green Chief Legal Officer, Chief SVP Corporate VP
Slide 31: Strong Momentum and Milestones Achieved
Strong Momentum and Milestones Achieved IPO October 2018 Antibody Design Capability and Drug Discovery June 2018 eCommerce Launch for Synbio May 2018 Long Term Contract Expanded to 1.3 billion bp - March 2018 NGS Launch AGBT February 2018 Data Storage Demonstration - May 2016 Beta Access Commercial
Slide 32: Significant opportunities to drive further growth
Significant opportunities to drive further growth Proprietary drug development Data storage partnerships Establish and revenue partnerships for drug discovery & Launch antibody development discovery / development Generate scale business efficiencies Expand gene and expand product offering in China t
Slide 33: Why Twist?
Why Twist? High Revenue Growth 2017-2018 revenue growth Broad Application from $10.8M to $25.4M Breakthrough Technology Multiple Product st Categories 1 DNA Writing on Silicon Platform and End Markets Large Growing Markets Synthesis DNA, NGS TE, Drug Discovery and Data Storage Unique Platform & Valu
Twist Bioscience — 37th Annual JPM Healthcare Conference 2019 on 6ix